About the Authors

Ricardo J. T. Ribeiro

oriebir.r@gmail.com

Affiliations Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal, Division of Cancer Epidemiology, Department of Oncology, McGill University, Montreal, Canada, LPCC–Portuguese League Against Cancer (NRNorte), Porto, Portugal

Cátia P. D. Monteiro

Affiliations Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, LPCC–Portuguese League Against Cancer (NRNorte), Porto, Portugal

Andreia S. M. Azevedo

Affiliations Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, LPCC–Portuguese League Against Cancer (NRNorte), Porto, Portugal

Virgínia F. M. Cunha

Affiliations Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, LPCC–Portuguese League Against Cancer (NRNorte), Porto, Portugal

Agnihotram V. Ramanakumar

Affiliation Division of Cancer Epidemiology, Department of Oncology, McGill University, Montreal, Canada

Avelino M. Fraga

Affiliations Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal, Urology Department, D. Pedro V Military Hospital, Porto, Portugal

Francisco M. Pina

Affiliation Urology Department, S. João Hospital, Porto, Portugal

Carlos M. S. Lopes

Affiliation ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal

Rui M. Medeiros

Affiliations Molecular Oncology Group-CI, Portuguese Institute of Oncology, Porto, Portugal, ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal, LPCC–Portuguese League Against Cancer (NRNorte), Porto, Portugal

Eduardo L. Franco

Affiliation Division of Cancer Epidemiology, Department of Oncology, McGill University, Montreal, Canada

Competing Interests

The authors have read the journal's policy and have the following conflicts: Co-author Rui Medeiros is a PLoS ONE Editorial Board member. The authors received funding from Novartis Oncology Portugal. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: RJTR FMP CMSL RMM ELF. Performed the experiments: RJTR CPDM ASMA VFMC AMF FMP. Analyzed the data: RJTR AVR ELF. Contributed reagents/materials/analysis tools: RJTR CMSL RMM. Wrote the paper: RJTR ELF.